Signals, Powered By EquityPandit
Glenmark Pharmaceuticals has got the final approval from the US health regulator for generic version of Strattera Capsules that are used in treating attention-deficit/hyperactivity disorder (ADHD).
Glenamrk Pharmaceuticals has said in a BSE filing that “Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U S FDA) for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the generic version of Strattera Capsules of Eli Lilly and Company.”
Glenmark has said that as per IMS Health sales data for the 12 months to April 2017, the Strattera capsules achieved annual sales of approximately USD 1.1 billion.
